Wireless Confidentiality Clause

Sanofi Chimie ordered to review its social

.

Employees and unions have fought for months against plans to restructure the company SANOFI first French pharmaceutical company.

They come to get their first victory: the court of Nanterre has canceled the plan to restructure the company, noting "the inadequacy and irregularity of the procedure for information and consultation" launched March 31, 2010 .

The first company in the CAC 40 was therefore outside the law!

The company SANOFI-AVENTIS pharmaceutical company is the fourth in the world with 28,000 employees. It was merged in 2004, the French group Sanofi-Synthelabo and the German group Aventis.

Its turnover in 2009 was 29 billion euros (+ 6.3% compared to 2008) and its profits were $ 8.5 billion. The company has yet eliminated 3,000 jobs in 2009-2010, including 1300 in the field of research. In 2010, wages will rise only 1.2% (against + 9.1% for dividends to shareholders).

The annual result of Sanofi has of course been boosted by record sales of vaccines with the epidemic influenza A. Orders for influenza vaccine (H1N1 and seasonal influenza) Mrs Roselyne Bachelot-Narquin, amounted to over 1 billion euros, an increase of 46% over 2008!

The group has also engaged handsome profits on public health (non-prescription drugs such as Doliprane).

strategy at the expense of employees, research and health

For years, the laboratories of Sanofi failed to produce real therapeutic innovations. Now they must face patent expiry of many of their flagship products, the famous blockbusters (drugs with sales over one billion dollars), which then fall into the field of generic, sold cheaper.

To achieve the same figures show business in years to come, the French multinational, like the dozen groups that dominate the global market, has started work on inventing a new "model economic. " The proposed reorganization "transforming" aims to achieve 2 billion euros in savings by 2013:

- Investment in generics (Sanofi acquired the generic companies in the Czech Republic, Brazil, Mexico)

- Maximum pressure on costs

- transfer of production sites

- Outsourcing Research: considered too costly, she is hit first.

Sanofi plans to close eight research sites, including 4 in France and the rest of the UK, Spain, Japan and the United States. The company seeks partnerships with government structures to shift some financial risk. "There is no measurement between the costs of external research, which benefits from public subsidies and government, and that of the internal, where we take care of everything, "according to the head of R & D at Sanofi-Aventis.

Sanofi does not invest in research but no expense to increase acquisitions: $ 8.5 billion for operations conducted since 2008. The objectives that should prevail in this sector (response to therapeutic expectations unfulfilled, providing treatments at affordable prices all over the world) are sidelined for the benefit of the added value of shareholders.

Sanofi-Aventis will heal its social

In an interim order of August 12, the Tribunal de Grande Instance de Nanterre (Hauts-de-Seine) Sanofi forced a reappraisal. "The procedure will be repeated from the beginning, Sanofi is to present a coherent plan and a backup plan for employment (PSE) which certainly can be amended following meetings of the CEC (Central Committee of enterprise), but which must be comprehensive in their fundamental aspects from the beginning, "says the order.

Hope so

among employees. While the leadership group chemistry had to delete 904 positions, based on voluntary departures, in sites of Neuville-sur-Saône (Rhône) and Romainville (Seine-Saint-Denis), the court pointed to "the irregularity "and" lack "of information and consultation procedure of the backup plan for employment (PSE).

Entering through the coordination of the CGT of Sanofi, the company will resume the process from A to Z under penalty of a fine of 1,000 euros per day of delay from August 31, 2010. Thierry Bodin, national coordinator CGT, the court victory is a first step. "We hope that management is reviewing its copy and maintain both sites. We'll call the departmental labor, local elected officials to preserve the most jobs. "

Nicolas Sarkozy this strategy encourages the pharmaceutical industry including Sanofi-Aventis is the emblematic example

October 26, 2009, the Strategic Council for the Healthcare Industry (CSIS), comprising the heads of major French pharmaceutical companies, was received at the Elysee. "The income from your business will decrease by 20, 30 or 40%, "said Nicolas Sarkozy, before patterns of CSIS. For the president, this" historic collapse "is exclusively due to the" generic "drugs.

Several measures will subsidize pharmaceutical industry:

- Creating a fund for investment in health biotechnology start with 130 million euros, financed half by the state.

- Deleting business tax of 16% will lighten the burden on businesses

- The research tax credit reform in 2008 and renewed for 2010 will allow companies to be reimbursed 30% of their expenditure on research and development (R & D)

- "domestic borrowing would finance some investments," including the creation of institutes hospital university-private partnership.

Five of these institutions will also accredited in 2010 (the exact number of firms represented in the Strategic Council for its members called G5: Sanofi-Aventis, Pierre Fabre, Servier, Ipsen and Biotechnology Laboratory splitting ).

In France, the share of Research has already increased from 2.24% of GDP in 2002 to 2.02% in 2008, according to the association "Save Research". By continuing to simplify the organization of research in Life Sciences and Health, the government will unfortunately result in a new drying up of financing for public research to help French force her to accept public-private partnerships ...